Oric Pharmaceuticals
Tucker Roberts is an experienced professional in medicinal chemistry, currently serving as Associate Director at ORIC Pharmaceuticals Inc. since January 2021. Prior to this role, Tucker held various positions at Aduro Biotech from October 2016 to January 2021, progressing from Scientist II to Senior Scientist and ultimately to Associate Director in Medicinal Chemistry. Tucker's career began at RQx Pharmaceuticals, where roles included Scientist I and Scientist II from November 2010 to February 2016. Tucker holds a PhD in Organic Chemistry from Scripps Research (2004-2010), a Second Major in Chemistry from Columbia University (2002-2004), and a Bachelor of Applied Science in Political Science and Government from Vanderbilt University (1997-2001).
This person is not in any teams
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.